In AIH patients, it has been shown that autologous Foxp3+ TREG cell therapy is feasible and safe, and interestingly a strong preferential homing of Foxp3+ TREG cells to the liver and spleen was observed for up to 72 h. The gene discussed is FOXP3; the disease is autoimmune hepatitis.